AM
AMS.LSE Advanced Medical Solutions Group plc
- Market cap
- GBX 615M
- P/E
- 141.3x
- P/B
- 2.42x
- ROE
- -0.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is AMS.LSE undervalued?
Graham numberThe Graham number of Advanced Medical Solutions Group plc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Advanced Medical Solutions Group plc fundamental analysis
No fundamental analysis for Advanced Medical Solutions Group plc yet.
Advanced Medical Solutions Group plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Advanced Medical Solutions Group plc
Advanced Medical Solutions Group plc, together with its subsidiaries, develops, manufactures, and distributes products for the surgical, woundcare, and wound-closure markets in the United Kingdom, Germany, France, Europe, the United States, and internationally. It offers surgical products, such as tissue adhesives, sutures and clips, haemostats, biosurgical, internal fixation devices, infection control, and internal sealants. The company also provides collagens, bone substit…
Full company profileAdvanced Medical Solutions Group plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Advanced Medical Solutions Group plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 83.2M | 96.9M | 103M | 102M | 86.8M | 109M | 124M | 126M | 178M | 229M | 462M |
| Gross Profit | 48.0M | 58.4M | 63.4M | 57.8M | 42.7M | 56.1M | 68.6M | 70.1M | 82.8M | 109M | 223M |
| Operating Income | 19.5M | 25.2M | 28.9M | 27.7M | 10.7M | 23.0M | 24.9M | 18.9M | 10.5M | 22.0M | 59.2M |
| EBITDA | 22.4M | 28.2M | 32.9M | 30.1M | 17.5M | 31.5M | 34.9M | 31.4M | 29.7M | 43.4M | 104M |
| Net Income | 15.7M | 20.1M | 22.7M | 18.9M | 8.58M | 17.5M | 20.4M | 15.9M | 7.09M | 9.95M | -260K |
| EPS | 0.07 | 0.09 | 0.10 | 0.09 | 0.04 | 0.08 | 0.09 | 0.07 | 0.03 | 0.05 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 145M | 169M | 205M | 227M | 239M | 250M | 281M | 289M | 389M | 395M | 392M |
| Total Liabilities | 19.5M | 16.3M | 32.5M | 35.7M | 36.3M | 36.8M | 44.5M | 45.0M | 147M | 135M | 137M |
| Shareholders' Equity | 126M | 152M | 173M | 191M | 202M | 213M | 237M | 244M | 241M | 259M | 254M |
| Cash & Short-term Investments | 51.1M | 62.5M | 76.4M | 64.8M | 53.8M | 73.0M | 82.3M | 60.2M | 17.0M | 18.0M | 13.6M |
| Total Debt | - | - | 10.0M | 10.4M | 11.1M | 9.86M | 9.75M | 9.14M | 89.7M | 81.5M | 85.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 19.8M | 17.0M | 21.7M | 21.7M | 21.5M | 31.0M | 26.9M | 12.3M | 19.5M | 28.7M | 17.7M |
| Capital Expenditure | 1.52M | 2.90M | 3.06M | 5.85M | 5.26M | 6.46M | 9.96M | 9.85M | 4.06M | 7.36M | 29.7M |
| Free Cash Flow | 18.3M | 14.1M | 18.6M | 15.8M | 16.3M | 24.6M | 16.9M | 2.50M | 12.7M | 21.4M | -12.0M |
| Ratios | |||||||||||
| ROE | 12.5% | 13.2% | 13.1% | 9.9% | 4.2% | 8.2% | 8.6% | 6.5% | 2.9% | 3.8% | -0.1% |
| ROA | 10.8% | 11.9% | 11.0% | 8.3% | 3.6% | 7.0% | 7.3% | 5.5% | 1.8% | 2.5% | -0.1% |
| Net Profit Margin | 18.9% | 20.8% | 22.1% | 18.5% | 9.9% | 16.1% | 16.4% | 12.6% | 4.0% | 4.3% | -0.1% |
| Debt to Equity | - | - | 0.06x | 0.05x | 0.05x | 0.05x | 0.04x | 0.04x | 0.37x | 0.32x | 0.34x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Advanced Medical Solutions Group plc dividends
- Dividend yield
- -
- Forward dividend
- 0.01 GBX
- Payout ratio
- 58.2%
- Ex-dividend date
- Sep 25, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | GBP 5.79M | 0.03 | 58.2% |
| 2024 | GBP 5.20M | 0.02 | 73.3% |
| 2023 | GBP 4.78M | 0.02 | 30.1% |
| 2022 | GBP 4.34M | 0.02 | 21.3% |
| 2021 | GBP 3.85M | 0.02 | 22.0% |
| 2020 | GBP 3.34M | 0.02 | 38.9% |
| 2019 | GBP 3.01M | 0.01 | 15.9% |
| 2018 | GBP 2.49M | 0.01 | 11.0% |
| 2017 | GBP 2.05M | 0.01 | 10.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10000:10104 on Apr 2, 2002.
Who owns Advanced Medical Solutions Group plc
- Insiders 8.04%
- Institutions 72.50%
- Public & others 19.46%
- Shares outstanding 218M
- Free float 190M
Advanced Medical Solutions Group plc company profile
- Company name
- Advanced Medical Solutions Group plc
- Ticker
- AMS.LSE
- ISIN
- GB0004536594
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,800
- Fiscal year end
- December
- Address
- Premier Park, Winsford, United Kingdom, CW7 3RT
- Phone
- 44 1606 863 500
- Website
- admedsol.com
About Advanced Medical Solutions Group plc
Advanced Medical Solutions Group plc, together with its subsidiaries, develops, manufactures, and distributes products for the surgical, woundcare, and wound-closure markets in the United Kingdom, Germany, France, Europe, the United States, and internationally. It offers surgical products, such as tissue adhesives, sutures and clips, haemostats, biosurgical, internal fixation devices, infection control, and internal sealants. The company also provides collagens, bone substitutes, resorbable fixation systems, vascular temporary occlusion, dressings, silicone wound contact layers, surgical supplies, debridement, hydrogels, and laparoscopic instruments. It sells its products under the LIQUIFIX, Peters Surgical, Ifabond, INTEGUSEAL, LiquiBand, RESORBA, LiquiBandFix8, Seal-G, Vitalitec, and ActivHeal brand names. The company provides wound care dressings, including silver alginates, alginates, and foams through its ActivHeal brand, as well as under white label. Advanced Medical Solutions Group plc was founded in 1991 and is headquartered in Winsford, the United Kingdom.
Advanced Medical Solutions Group plc management
8- Mr. Andrew Christopher Meredith BSc (Hons)CEO & Executive Director · born 1966
- Mr. Edward Johnson ACACFO, ESG Lead & Executive Director · born 1972
- Dr. Alexandra Dietrich Ph.D.Chief Operating Officer · born 1975
- Mr. Michael Edward KingInvestor Relations Manager
- Simon SwainHead of Legal
- Ms. Cathy TomlinsonChief People Officer
- Mr. Ross McDonaldChief Commercial Officer
- Mr. Owen John BromleyCompany Secretary